Neuroprotective agents in Parkinson's disease: Clinical evidence and caveats

Neurologic Clinics

Volumn 22, Issue 3 SUPPL., 2004, Pages

  Hälbig, Thomas D ^a   Tse, Winona ^a   Olanow, C Warren ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCARNITINE; ALPHA TOCOPHEROL; AMANTADINE; ANTIOXIDANT; APOPTOSIS INHIBITOR; BENZENE DERIVATIVE; BROMOCRIPTINE; CEP 1347; CREATINE; DIBENZO[B,F]OXEPIN 10 YLMETHYLPROP 2 YNYLAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GINKGO BILOBA EXTRACT; GLUTAMATE RECEPTOR ANTAGONIST; LAZABEMIDE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINAMIDE; NORSELEGILINE; PRAMIPEXOLE; RASAGILINE; RIBOFLAVIN; RILUZOLE; ROPINIROLE; ROTENONE; SELEGILINE; TCH 346; THIOCTIC ACID; UBIDECARENONE; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; NEUROPROTECTIVE AGENT;

BRAIN MITOCHONDRION; CELL DEATH; CLINICAL TRIAL; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; EXCITOTOXICITY; GAIT; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MEDICAL DECISION MAKING; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; UPREGULATION; BRAIN; DRUG COMBINATION; DRUG EFFECT;

ANTIPARKINSON AGENTS; BRAIN; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 16544376799     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2004.07.002     Document Type: Review

References (89)

1. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
2. T.T. Warner, and A.H. Schapira Genetic and environmental factors in the cause of Parkinson's disease Ann Neurol 53 Suppl 3 2003 S16 S23 [discussion S23-25]
3. M.C. Dekker, V. Bonifati, and C.M. van Duijn Parkinson's disease: piecing together a genetic jigsaw Brain 126 2003 1722 1733
4. C.M. Tanner Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies Adv Neurol 91 2003 133 142
5. A.H.V. Schapira, and C.W. Olanow Neuroprotection in Parkinson's disease: mysteries, myths, and misconceptions JAMA 291 2004 358 364
6. P. Jenner, and C.W. Olanow Understanding cell death in Parkinson's disease Ann Neurol 44 3 Suppl 1 1998 S72 S84
7. K.S. McNaught, C.W. Olanow, B. Halliwell, O. Isacson, and P. Jenner Failure of the ubiquitin-proteasome system in Parkinson's disease Nat Rev Neurosci 2 2001 589 594
8. C.W. Olanow, D.P. Perl, G.N. DeMartino, and K. McNaught Lewy bodies are aggresome-related inclusions: a hypothesis Lancet Neurol 3 2004 496 503
9. P. Jenner Oxidative stress in Parkinson's disease Ann Neurol 53 Suppl 3 2003 S26 S36 [discussion S36-8]
10. K.U. Ingold, A.C. Webb, D. Witter, G.W. Burton, T.A. Metcalfe, and D.P. Muller Vitamin E remains the major lipid-soluble, chain-breaking antioxidant in human plasma even in individuals suffering severe vitamin E deficiency Arch Biochem Biophys 259 1987 224 225
11. L. Packer, and S. Landvik Vitamin E in biological systems Adv Exp Med Biol 264 1990 93 103
12. K. Chiba, A. Trevor, and N. Castagnoli Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase Biochem Biophys Res Commun 120 1984 574 578
13. G. Cohen, P. Pasik, B. Cohen, A. Leist, C. Mytilineou, and M.D. Yahr Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in monkeys Eur J Pharmacol 106 1984 209 210
14. C.W. Olanow Oxidation reactions in Parkinson's disease Neurology 40 10 Suppl 3 1990 32 37
15. A.A. Boulton Symptomatic and neuroprotective properties of the aliphatic propargylamines Mech Ageing Dev 111 1999 201 209
16. M.B. Youdim, and M. Weinstock Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R) aminoindan-5-YL)-ethyl methyl carbamate] Cell Mol Neurobiol 21 2001 555 573
17. Parkinson Study Group DATATOP: a multicenter controlled clinical trial in early Parkinson's disease Arch Neurol 46 1989 1052 1060
18. The Parkinson Study Group Effect of deprenyl on the progression of disability in early Parkinson's disease N Engl J Med 321 1989 1364 1371
19. The Parkinson Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease N Engl J Med 328 1993 176 183
20. N. Giladi, M.P. McDermott, S. Fahn, S. Przedborski, J. Jankovic, and M. Stern Freezing of gait in PD: prospective assessment in the DATATOP cohort Neurology 56 2001 1712 1721
21. C.W. Olanow, and D. Calne Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology 42 1991 13 26
22. Parkinson Study Group Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa Ann Neurol 39 1996 29 36
23. Parkinson Study Group Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa Ann Neurol 39 1996 37 45
24. H. Przuntek, B. Conrad, J. Dichgans, P.H. Kraus, P. Krauseneck, and G. Pergande SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa Eur J Neurol 6 1999 141 150
25. C.W. Olanow, R.A. Hauser, L. Gauger, T. Malapira, W. Koller, and J. Hubble The effect of deprenyl and levodopa on the progression of Parkinson's disease Ann Neurol 38 1995 771 777
26. The Parkinson Study Group Effect of lazabemide on the progression of disability in early Parkinson's disease Ann Neurol 40 1996 99 107
27. J. Emerit, M. Edeas, and F. Bricaire Neurodegenerative diseases and oxidative stress Biomed Pharmacother 58 2004 39 46
28. A.H. Schapira, J.M. Cooper, D. Dexter, J.B. Clark, P. Jenner, and C.D. Marsden Mitochondrial complex I deficiency in Parkinson's disease J Neurochem 54 1990 823 827
29. W.D. Parker Jr., S.J. Boyson, and J.K. Parks Abnormalities of the electron transport chain in idiopathic Parkinson's disease Ann Neurol 26 1989 719 723
30. L. Tretter, I. Sipos, and V. Adam-Vizi Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease Neurochem Res 29 2004 569 577
31. W.J. Nicklas, I. Vyas, and R.E. Heikkila Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine Life Sci 36 1985 2503 2508
32. R. Betarbet, T.B. Sherer, G. MacKenzie, M. Garcia-Osuna, A.V. Panov, and J.T. Greenamyre Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat Neurosci 3 2000 1301 1306
33. M.F. Beal Experimental models of Parkinson's disease Nat Rev Neurosci 2 2001 325 334
34. S.M. Fleming, C. Zhu, and P.-O. Fernagut Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone Exp Neurol 187 2004 418 429
35. M.F. Beal Bioenergetic approaches for neuroprotection in Parkinson's disease Ann Neurol 53 Suppl 3 2003 S39 S47 [discussion S47-8]
36. M.F. Beal, R.T. Matthews, A. Tieleman, and C.W. Shults Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice Brain Res 783 1998 109 114
37. R.T. Matthews, R.J. Ferrante, P. Klivenyi, L. Yang, A.M. Klein, and G. Mueller Creatine and cyclocreatine attenuate MPTP neurotoxicity Exp Neurol 157 1999 142 149
38. C.W. Shults, D. Oakes, K. Kieburtz, M.F. Beal, R. Haas, and S. Plumb Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline Arch Neurol 59 2002 1541 1550
39. S.A. Lipton, and P.A. Rosenberg Excitatory amino acids as a final common pathway for neurologic disorders N Engl J Med 330 1994 613 622
40. R.J. White, and I.J. Reynolds Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure J Neurosci 16 1996 5688 5697
41. F. Blandini, R.H. Porter, and J.T. Greenamyre Glutamate and Parkinson's disease Mol Neurobiol 12 1996 73 94
42. M.C. Rodriguez, J.A. Obeso, and C.W. Olanow Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection Ann Neurol 44 3 Suppl 1 1998 S175 S188
43. C.W. Olanow, and W.G. Tatton Etiology and pathogenesis of Parkinson's disease Annu Rev Neurosci 22 1999 123 144
44. A. Doble The role of excitotoxicity in neurodegenerative disease: implications for therapy Pharmacol Ther 81 1999 163 221
45. L. Turski, K. Bressler, K.J. Rettig, P.A. Loschmann, and H. Wachtel Protection of substantia nigra from MPP + neurotoxicity by N-methyl-D-aspartate antagonists Nature 349 1991 414 418
46. J.T. Greenamyre, R.V. Eller, Z. Zhang, A. Ovadia, R. Kurlan, and D.M. Gash Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease Ann Neurol 35 1994 655 661
47. B. Piallat, A. Benazzouz, and A.L. Benabid Subthalamic nucleus lesion on rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies Eur J Neurosci 8 1996 1408 1414
48. R.J. Uitti, A.H. Rajput, J.E. Ahlskog, K.P. Offord, D.R. Schroeder, and M.M. Ho Amantadine treatment is an independent predictor of improved survival in Parkinson's disease Neurology 46 1996 1551 1556
49. A. Doble The pharmacology and mechanism of action of riluzole Neurology 47 6 Suppl 4 1996 S233 S241
50. T. Araki, T. Kumagai, K. Tanaka, M. Matsubara, H. Kato, and Y. Itoyama Neuroprotective effect of riluzole in MPTP-treated mice Brain Res 918 2001 176 181
51. M.C. Obinu, M. Reibaud, V. Blanchard, S. Moussaoui, and A. Imperato Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence Mov Disord 17 2002 13 19
52. J. Jankovic, and C. Hunter A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease Parkinsonism Relat Disord 8 2002 271 276
53. O. Rascol, W. Olanow, D. Brooks, G. Koch, P. Truffinet, and R. Bejuit A 2-year, multicenter, placebo-controlled, double-blind, parallel-group study of the effect of riluzole on Parkinson's disease progression Mov Disord 17 Suppl 5 2002 P80
54. N.A. Tatton, A. Maclean-Fraser, W.G. Tatton, D.P. Perl, and C.W. Olanow A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease Ann Neurol 44 3 Suppl 1 1998 S142 S148
55. C. Mytilineou, P. Radcliffe, E.K. Leonardi, P. Werner, and C.W. Olanow L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro J Neurochem 68 1997 33 39
56. C. Mytilineou, P.M. Radcliffe, and C.W. Olanow L-(-)-desmethylselegiline, a metabolite of L-(-)-selegiline, protects mesencephalic dopamine neurons from excitotoxicity in vitro J Neurochem 68 1997 434 436
57. W.G. Tatton, W.Y. Ju, D.P. Holland, C. Tai, and M. Kwan (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis J Neurochem 63 1994 1572 1575
58. W.G. Tatton, R.M. Chalmers-Redman, W.J. Ju, M. Mammen, G.W. Carlile, and A.W. Pong Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells J Pharmacol Exp Ther 301 2002 753 764
59. G.W. Carlile, R.M. Chalmers-Redman, N.A. Tatton, A. Pong, K.E. Borden, and W.G. Tatton Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer Mol Pharmacol 57 2000 2 12
60. R. Ishitani, K. Sunaga, A. Hirano, P. Saunders, N. Katsube, and D.M. Chuang Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture J Neurochem 66 1996 928 935
61. A. Sawa, A.A. Khan, L.D. Hester, and S.H. Snyder Glyceraldehyde-3- phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death Proc Natl Acad Sci USA 94 1997 11669 11674
62. P.C. Waldmeier, A.A. Boulton, A.R. Cools, A.C. Kato, and W.G. Tatton Neurorescuing effects of the GAPDH ligand CGP 3466B J Neural Transm Suppl 2000 197 214
63. E. Kragten, I. Lalande, K. Zimmermann, S. Roggo, P. Schindler, and D. Muller Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl J Biol Chem 273 1998 5821 5828
64. Parkinson Study Group The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD Neurology 62 2004 330 332
65. D.B. Calne, K. Burton, J. Beckman, and W.R. Martin Dopamine agonists in Parkinson's disease Can J Neurol Sci 11 1 Suppl 1984 221 224
66. Parkinson Study Group Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial JAMA 284 2000 1931 1938
67. O. Rascol, D.J. Brooks, A.D. Korczyn, P.P. De Deyn, C.E. Clarke, and A.E. Lang A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group N Engl J Med 342 2000 1484 1491
68. C.W. Olanow, P. Jenner, and D. Brooks Dopamine agonists and neuroprotection in Parkinson's disease Ann Neurol 44 3 Suppl 1 1998 S167 S174
69. A.H. Schapira, and C.W. Olanow Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease Ann Neurol 53 Suppl 3 2003 S149 S157 [discussion S157-49]
70. A.J. Carter, and R.E. Muller Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo Eur J Pharmacol 200 1991 65 72
71. N. Ogawa, K. Tanaka, M. Asanuma, M. Kawai, T. Masumizu, and M. Kohno Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro Brain Res 657 1994 207 213
72. M. Yoshioka, K. Tanaka, I. Miyazaki, N. Fujita, Y. Higashi, and M. Asanuma The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals Neurosci Res 43 2002 259 267
73. D.S. Cassarino, C.P. Fall, T.S. Smith, and J.P. Bennett Jr. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion J Neurochem 71 1998 295 301
74. V.D. Nair, C.W. Olanow, and S.C. Sealfon Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines Biochem J 373 2003 25 32
75. Parkinson Study Group Dopamine transporter brain imaging to assess the effectsof pramipexole vs levodopa on Parkinson disease progression JAMA 287 2002 1653 1661
76. A.L. Whone, R.L. Watts, A.J. Stoessl, M. Davis, S. Reske, and C. Nahmias Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study Ann Neurol 54 2003 93 101
77. K. Marek, R. Innis, C. van Dyck, B. Fussell, M. Early, and S. Eberly [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression Neurology 57 2001 2089 2094
78. P.K. Morrish, J.S. Rakshi, D.L. Bailey, G.V. Sawle, and D.J. Brooks Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET J Neurol Neurosurg Psychiatry 64 1998 314 319
79. D.J. Brooks, K.A. Frey, K.L. Marek, D. Oakes, D. Paty, and R. Prentice Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease Exp Neurol 184 Suppl 1 2003 S68 S79
80. J.E. Ahlskog Slowing Parkinson's disease progression: recent dopamine agonist trials Neurology 60 2003 381 389
81. Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson disease? The results of the Elldopa study. N Engl J Med, in press.
82. Parkinson Study Group A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study Arch Neurol 59 2002 1937 1943
83. F. Blandini, M.T. Armentero, R. Fancellu, E. Blaugrund, and G. Nappi Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease Exp Neurol 187 2004 455 459
84. M.B. Youdim, T. Amit, M. Falach-Yogev, O.B. Am, W. Maruyama, and M. Naoi The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-parkinson drug, rasagiline Biochem Pharmacol 66 2003 1635 1641
85. M. Naoi, W. Maruyama, M.B. Youdim, P. Yu, and A.A. Boulton Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase Inflammopharmacology 11 2003 175 181
86. Parkinson Study Group A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease Arch Neurol 61 2004 561 566
87. K.St.P. McNaught, D.P. Perl, A.-L. Brownell, and C.W. Olanow Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease Ann Neurol 56 2004 149 162
88. H. Braak, K.D. Tredici, and U. Rub Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 24 2003 197 211
89. M.J. Zigmond, E.D. Abercrombie, T.W. Berger, A.A. Grace, and E.M. Stricker Compensations after lesions of central dopaminergic neurons: some clinical and basic implications Trends Neurosci 13 1990 290 296